Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy.
drug assay
plasma
rufinamide
saliva
therapeutic drug monitoring
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
12
05
2020
revised:
27
05
2020
accepted:
27
05
2020
pubmed:
21
6
2020
medline:
1
12
2020
entrez:
21
6
2020
Statut:
ppublish
Résumé
The assay of saliva samples provides a valuable alternative to the use of blood samples for therapeutic drug monitoring (TDM), at least for certain categories of patients. To determine the feasibility of using saliva sampling for the TDM of rufinamide, we compared rufinamide concentrations in paired samples of saliva and plasma collected from 26 patients with epilepsy at steady state. Within-patient relationships between plasma rufinamide concentrations and dose, and the influence of comedication were also investigated. Assay results in the two tested fluids showed a good correlation (r
Substances chimiques
Anticonvulsants
0
Triazoles
0
rufinamide
WFW942PR79
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e79-e84Subventions
Organisme : IRCCS Mondino Foundation (Ricerca Corrente 2009-2011).
Pays : International
Informations de copyright
© 2020 International League Against Epilepsy.
Références
Banzel (rufinamide). Full prescribing information. Woodcliff Lake, NJ: Eisai. Last revised February 2015. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf. Accessed April 16, 2020.
Inovelon (rufinamide). Summary of product characteristics. Hatfield, UK: Eisai. Last revised July 2019. Available at: https://www.medicines.org.uk/emc/product/410/smpc . Accessed April 16, 2020.
Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123-41.
Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239-76.
Patsalos PN, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther Drug Monit. 2013;35:4-29.
Kim DY, Moon J, Shin YW, et al. Usefulness of saliva for perampanel therapeutic drug monitoring. Epilepsia. 2020;1-9. doi: 10.1111/epi.16513.
Brandt C, Bien CG, Helmer R, May TW. Assessment of the correlations of lacosamide concentrations in saliva and serum in patients with epilepsy. Epilepsia. 2018;59:e34-9.
Mazzucchelli I, Rapetti M, Fattore C, et al. Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. Anal Bioanal Chem. 2011;401:1013-21.
Patsalos PN, Zugman M, Lake C, et al. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia. 2017;58:1234-43.
Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet. 1999;36:453-70.
May TW, Boor R, Rambeck B, et al. Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2011;33:214-21.
Xu M, Ni Y, Zhou Y, et al. Pharmacokinetics and tolerability of rufinamide following single and multiple oral doses and effect of food on pharmacokinetics in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2016;41:541-8.
Arzimanoglou A, Ferreira JA, Satlin A, et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. Eur J Paediatr Neurol. 2016;20:393-402.
Williams ET, Carlson JE, Lai WG, et al. Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011;5:280-9.